In samples without 1p/19q co-deletion (Figures 1E, F), without MGMT promoter methylation (Figures 1G, H), and in IDH wild-type glioma patients (Figures 1I, J), we also found that patients had higher SIGLEC7 levels compared to the control group. This evidence concerns the gene MGMT and central nervous system cancer.